INO - Inovio Pharmaceuticals Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
2024-05-14 16:44:07 ET
Inovio Pharmaceuticals, Inc. (INO)
The Citizens JMP Life Sciences Conference
May 14, 2024, 11:30 AM ET
Company Participants
Jacqueline Shea - CEO
Conference Call Participants
Roy Buchanan - Citizens JMP
Presentation
Roy Buchanan
Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst. And we're happy to have Inovio Pharmaceuticals here with us. And we've got Jackie Shea, she's the Chief Executive Officer. So certainly exciting time at Inovio. Earnings call yesterday, if anybody listened, a lot going on. So maybe first, Jackie, just give us a quick background of the company for people not familiar, what the technology is, what it does, and maybe talk a bit about how you joined, why you joined and…?
Jacqueline Shea
Yes, sure. So thanks very much for having us. So Inovio is a clinical stage biotechnology company. We're focused on developing and commercializing DNA medicines in the areas of HPV related diseases, oncology and infectious diseases. We deliver our DNA medicines using a proprietary delivery device called CELLECTRA. And we're very focused at the moment in terms of developing our lead program, INO-3107, where we're looking to file our BLA in the second half of the year.
And following on behind 3107, we have a deep pipeline of other late stage assets as well as some earlier stage assets following on. So one of the reasons why I joined Inovio was I was incredibly excited, by the platform. DNA medicines have been around for a very long while, same as mRNA medicines. And what really attracted me to Inovio was that I felt that Inovio had solved the delivery problem for DNA medicines in the same way that lipid nanoparticles had solved the delivery problem for the mRNA medicines....
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)